Trial Profile
Gemcitabine and R115777 (Tipifarnib) Combination Therapy for Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Jan 2018
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Tipifarnib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 27 Jan 2018 Primary endpoint (Objective response rate (ORR)) has not been met, as per results published in the Investigational New Drugs.
- 27 Jan 2018 Results assessing efficacy of combination of tipifarnib and gemcitabine published in the Investigational New Drugs.
- 01 Jul 2013 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.